Abstract:As a key component in combination therapy for acquired immunodeficiency syndrome (AIDS), non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been proven to be an essential way in stopping HIV-1 replication. In the present work, in silico studies were conducted on a series of 119 NNRTIs, including 1-(2-hydroxyethoxymethyl)-6-(phenylthio)thymine (HEPT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives by using the comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), docking simulations and molecular dynamics (MD). The statistical results of the optimal model, the ligand-based CoMSIA one (Q 2 = 0.48, R ncv 2 =0.847, R pre 2 = 0.745) validates its satisfactory predictive capacity both internally and externally. The contour maps, docking and MD results correlate well with each other, drawing conclusions as follows: 1) Compounds with bulky substituents in position-6 of ring A, hydrophobic groups around position- 1, 2, 6 are preferable to the biological activities; 2) Two hydrogen bonds between RT inhibitor and the Tyr 318, Lys 101 residues, respectively, and a π-π bond between the inhibitor and Trp 188 are formed and crucial to the orientation of the active conformation of the molecules; 3) The binding pocket is essentially hydrophobic, which are determined by residues such as Trp 229, Tyr 318, Val 179, Tyr 188 and Val 108, and hydrophobic substituents may bring an improvement to the biological activity; 4) DABO and HEPT derivatives have different structures but take a similar mechanism to inhibit RT. The potency difference between two isomers in HEPTs can be explained by the distinct locations of the 6-naphthylmethyl substituent and the reasons are explained in details. All these results could be employed to alter the structural scaffold in order to develop new HIV-1 RT inhibitors that have an improved biological property. To the best of our knowledge, this is the first report on 3D-QSAR modeling of this series of HEPT and DABO NNRTs. The QSAR model and the information derived, we hope, will be of great help in presenting clear guidelines and accurate activity predictions for newly designed HIV-1 reverse transcriptase (RT) inhibitor.

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation of a Novel Thieno[3,4-D]pyrimidine Inhibitor Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Docking, Molecular Dynamics and Quantitative Structure-Activity Relationship Studies for HEPTs and DABOs As HIV-1 Reverse Transcriptase Inhibitors

Quantum mechanical analysis of newly synthesized HIV-1 protease inhibitors: evaluation of wild-type and resistant strain binding interactions

Advanced Molecular Mechanisms of Modified DRV Compounds in Targeting HIV-1 Protease Mutations and Interrupting Monomer Dimerization

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Preliminary SAR and Biological Evaluation of Potent HIV-1 Protease Inhibitors with Pyrimidine Bases As Novel P2 Ligands to Enhance Activity Against DRV-resistant HIV-1 Variants

Design and Evaluation of Novel Piperidine HIV-1 Protease Inhibitors with Potency Against DRV-resistant Variants

Docking Field-Based QSAR and Pharmacophore Studies on the Substituted Pyrimidine Derivatives Targeting HIV-1 Reverse Transcriptase

Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors

Receptor- and Ligand-Based 3D-QSAR Study for a Series of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods

Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657

Molecular Docking and 3D-QSAR Research of Diaryltriazines Derivatives as HIV-1 Reverse Transcriptase Inhibitors

3D-Qsar and Docking Studies on Piperidine-Substituted Diarylpyrimidine Analogues As Hiv-1 Reverse Transcriptase Inhibitors

Molecular modeling studies of dihydro-alkyloxy-benzyl-oxopyrimidines (DABOs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase using 3D-QSAR, Topomer CoMFA and molecular docking simulations

Identifying the Molecular Mechanics and Binding Dynamics Characteristics of Potent Inhibitors to HIV‐1 Protease